Perspectives on Nivo Rela vs Nivo Ipi ITC

In this Perspectives on the Science piece, we reflect on the recent indirect treatment comparison between RELATIVITY-047 and CheckMate-067

Authors

Affiliations

Saito, Jenny

National Institutes of Health

Brownell, Isaac

National Institutes of Health

Miller, David M.

Massachusetts General Hospital

Harvard Medical School

Featured Article

Long, G. V. et al. First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data. Journal of Clinical Oncology (2024) doi:10.1200/jco.24.01125.1

Introduction

Background

Study Design

Main Findings

Discussion

Survey Results

Role

Melanoma Experience

Advanced Melanoma Experience

Case One

Case Two

Propensity Score Experience

Comfort

Practice Changing

References

1.

Long, G. V. et al. First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data. Journal of Clinical Oncology (2024) doi:10.1200/jco.24.01125.

Citation

BibTeX citation:

@article{jenny2024,
  author = {Saito, Jenny and Brownell, Isaac and Miller, David M.},
  publisher = {Society of Cutaneous Oncology},
  title = {Perspectives on {Nivo} {Rela} Vs {Nivo} {Ipi} {ITC}},
  journal = {Journal of Cutaneous Oncology},
  volume = {2},
  number = {1},
  date = {2024-11-08},
  url = {https://journalofcutaneousoncology.io/perspectives/Vol_2_Issue_2/nivo_rela_nivo_ipi_itc},
  doi = {10.59449/joco.2024.11.08},
  issn = {2837-1933},
  langid = {en}
}

For attribution, please cite this work as:

Saito, Jenny, Brownell, Isaac & Miller, David M. Perspectives on Nivo Rela vs Nivo Ipi ITC. Journal of Cutaneous Oncology 2, (2024).